Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
Research Institute of Medical Cell Technologies, Yekaterinburg, Russian Federation.
Pediatr Blood Cancer. 2018 Nov;65(11):e27354. doi: 10.1002/pbc.27354. Epub 2018 Jul 14.
Detection of bone marrow (BM) involvement in patients with neuroblastoma is crucial for staging and defining prognosis. Furthermore, the persistence of residual tumor cells in the BM is associated with an unfavorable outcome.
Expression of PHOX2B, TH, ELAVL4, and B4GALNT1 (GD2-synthase) was analyzed by quantitative polymerase chain reaction in neuroblastoma cell lines, control BM samples, and in BM samples from patients. The threshold level of expression for each gene was established through receiver operator characteristic analysis and used to determine the diagnostic test performance. The prognostic significance of BM involvement was assessed by survival rates calculations. The median of follow-up time was 36.1 months.
Neither PHOX2B nor TH expression was detected in control BM, while expression of ELAVL4 was found in 20 (76.9%) and GD2-synthase in 15 (57.7%) of 26 samples. The overall correct predictive value for TH, ELAVL4, and GD2-synthase, based on thresholds levels, was 0.952, 0.828, and 0.767, respectively, whereas the overall correct predictive value for PHOX2B was 0.994. The PHOX2B/TH expression in diagnostic BM of patients with neuroblastoma corresponded with a decreased survival rate (P < 0.001) in the total cohort and in different risk groups. Predominance of normalized expression of PHOX2B over TH > 1.68 in the diagnostic BM samples demonstrated an adverse prognostic effect (P = 0.006). Persistence of PHOX2B/TH expression in the BM during and after induction chemotherapy resulted in dismal outcome (P = 0.022 and P = 0.012).
PHOX2B and TH are the most optimal markers for detection of BM involvement, allowing identification of high-risk patients. Predominance of PHOX2B expression over TH has a strong adverse prognostic impact.
在神经母细胞瘤患者中检测骨髓(BM)受累对于分期和确定预后至关重要。此外,BM 中残留肿瘤细胞的持续存在与不良预后相关。
通过定量聚合酶链反应分析神经母细胞瘤细胞系、对照 BM 样本和患者 BM 样本中 PHOX2B、TH、ELAVL4 和 B4GALNT1(GD2 合成酶)的表达。通过接收者操作特征分析确定每个基因的表达阈值水平,并用于确定诊断测试性能。通过生存曲线计算评估 BM 受累的预后意义。中位随访时间为 36.1 个月。
在对照 BM 中未检测到 PHOX2B 或 TH 表达,而在 26 个样本中的 20 个(76.9%)和 15 个(57.7%)中检测到 ELAVL4 和 GD2 合成酶表达。基于阈值水平,TH、ELAVL4 和 GD2 合成酶的总体正确预测值分别为 0.952、0.828 和 0.767,而 PHOX2B 的总体正确预测值为 0.994。神经母细胞瘤患者诊断性 BM 中的 PHOX2B/TH 表达与总队列和不同风险组中降低的生存率相关(P<0.001)。在诊断性 BM 样本中,PHOX2B 相对于 TH 的归一化表达大于 1.68 的优势表现出不良的预后效应(P=0.006)。在诱导化疗期间和之后 BM 中 PHOX2B/TH 表达的持续存在导致预后不良(P=0.022 和 P=0.012)。
PHOX2B 和 TH 是检测 BM 受累的最理想标志物,可识别高危患者。PHOX2B 表达优于 TH 具有强烈的不良预后影响。